B
B

Biogen


News

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States.
B

Lonza to buy back $2.17 bln worth of shares, backs mid-term growth

UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth Adds background on investments, headwinds By Ludwig Burger and Tristan Chabba Jan 25 (Reuters) - Lonza LONN.S on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future.
B
L

Lonza full-year earnings edge market expectations

Lonza full-year earnings edge market expectations Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. The Basel-based firm reported core EBITDA, or earnings before interest, taxes, depreciation, amortisation and special items, of 2.0 billion Swiss francs ($2.17 billion), up 19.8%.
B
L

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead

UPDATE 1-Eli Lilly Alzheimer's drug setback extends rival Biogen's lead Adds Biogen share movement, background, updates Eli Lilly shares Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
B

U.S. STOCKS Netflix, PagerDuty, Proterra

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rose on Friday after Netflix kicked off the earnings season for growth stocks on an upbeat note, while Google parent Alphabet gained on news of job cuts.
A
B
B
B
C
D
G
H
N
S
T
U
T
T
U
U
R

U.S. STOCKS Biogen, Wayfair, Costco

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Nasdaq futures rose on Friday, after Netflix kicked off the earnings season for the growth sector on a positive note, but worries about a U.S.
A
B
B
C
D
F
G
H
N
S
T
T
U
R

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. The U.S. Food and Drug Administration (FDA) declined to approve donanemab because Lilly had not submitted data from enough patients who were treated for at least a year, the drugmaker said late Thursda
B

Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

UPDATE 3-Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug Adds neurologist comments, patient advocacy group comment By Deena Beasley Jan 19 (Reuters) - Eli Lilly and Co LLY.N on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.
B

U.S. STOCKS Apple, Surmodics, Domino's

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Thursday as recession worries crept into the foreground of the earnings season, while shares of Procter & Gamble fell as it warned of cost pressures.
A
A
A
B
G
H
J
M
T
T
U
E
R

Eisai files for approval of Alzheimer's drug in Japan

(Updates with background) Jan 16 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen Inc BIIB.O , is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
B

Wall St rallies as jobs, services data calm rate hike worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * U.S. December payrolls up 223,000 vs est 200,000 * Dec. non-manufacturing PMI 49.6 vs November's 56.5 read * Biogen closes higher as FDA approves Alzheimer's drug * Indexes up: Dow 2.13%, S&P 2.28%, Nasdaq 2.56% By Sinéad Carew and Ankika Biswas Jan 6 (Reuters) - Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wag
B
B
C
P
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with detail on S&P 500 moving average, graphics) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with details following close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December (Updates with details at close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank
A
B
N
T
U
U

Wall Street rallies after Powell eyes slower rate hikes

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla up as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * S&P 500 +1.71%, Nasdaq +2.87%, Dow +0.93% By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street jumped on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December.
A
B
N
T
U
U

New York Times business news - Nov 30

Nov 30 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O released new data Tuesday evening, offering the first detailed look at the effects of the experimental Alzheimer's drug, lecanemab, suggesting that the treatment slowed cognitive decline for people in the early stages of the disease but also caused some patients to experience brain swel
B

Wall Street Journal - Nov 30

Nov 30 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Airbnb Inc ABNB.O is launching a listing service for rental apartments with some of the biggest landlords and property managers in the country, a bid to expand its business in multifamily buildings where owners often shun short-term rentals.
A
B
K

Wall Street ends down sharply, hit by Apple and China worries

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Cyber Monday spending to hit $11.6 bln - report * Crypto shares fall on BlockFi bankruptcy filing * Biogen down after death in Alzheimer drug trial * Indexes end: S&P 500 -1.54%, Nasdaq -1.58%, Dow -1.45% (Updates with details following end of trading session) By Ankika Biswas and Noel Randewich Nov 28 (Reuters) - U.S.
A
A
B
M
N
T
U
U



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.